# Laekna Therapeutics Shanghai Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/laekna-therapeutics-shanghai-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.laekna.com
- Total disclosed funding: $168M
- Latest round: Series D (May 18, 2022)
- Investors on record: 8

## About

Established in 2016 and based in Shanghai, China, Laekna Therapeutics Shanghai Co., Ltd. is a biopharmaceutical company that focuses on the research and development of new drugs for cancer and liver fibrosis. The company's core team members all have over 20 years of new drug development capabilities in both the US and China, with experience from drug development to market. Founder and CEO Dr. Xiangyang Lv has worked for Pfizer and the US biotech start-up company Curis. In June 2023, Laekna Therapeutics Shanghai Co., Ltd. raised HKD 680.121 million in pre-IPO funding. In June 2023, Laekna Therapeutics Shanghai Co., Ltd. was listed on Hong Kong Stock Exchange under the number 02105.

The company is mainly engaged in the research and development of new antitumor drugs. It has established a new drug research and development platform for liver diseases and tumors. Its products include the AKT inhibitor afuresertib, CYP17A1 and CYP11B2 dual-target inhibitors, etc. The products can be used to treat breast cancer, ovarian cancer, prostate cancer, and other cancer diseases.

The company generates revenue by providing new drugs for cancer and liver fibrosis.

## Funding rounds

- Series D, May 18, 2022, $61M — Infinity Group, CS Capital, Wanhuixin Fund, Yanchuang Capital
- Series C, Oct 1, 2020, $61M — Shenzhen Capital Real Estate Fund
- Series B, Apr 2, 2019, $28M — OrbiMed Advisors, GP Capital
- Series A, Jun 4, 2018, $19M — OrbiMed Advisors, AnlongMed Investment

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- AnlongMed Investment — Series A
- GP Capital (https://capitalatlas.ai/funds/gp-capital) — Series B
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series C
- Infinity Group (https://capitalatlas.ai/funds/infinity-group) — Series D
- CS Capital — Series D
- Wanhuixin Fund (https://capitalatlas.ai/funds/wanhuixin-fund) — Series D
- Yanchuang Capital (https://capitalatlas.ai/funds/yanchuang-capital) — Series D